Plus, the third-best analyst on Wall Street’s 44% upside call.
May 30, 2026
Aug 22, 2026
•
1 min read
Plus, a cancer-imaging play with a looming FDA date... and a whopping 95% implied upside.
Aug 15, 2026
Plus, the year’s biggest chip IPO still has plenty of room to run...
Aug 8, 2026
Plus, a Street-high target on a lagging tech giant...
